Clinical research of alpha glycerophosphocholine(GPC) has been over 30 years. (Kidd, 2007) GPC is a water soluble phospholipid metabolites found in the neuronal membrane. It is also an important neurotransmitter and phospholipid precursor. GPC exists in human milk, ox, pancreas, sardine, fox, rabbits and other mammal’s organization. GPC has great functions for the human body. It is able to go through the blood brain barrier and improve neuron’s ability. It can also adjust the conduction of nerve impulse, which can improve attention and memory, and characteristic curve of brain wave. (Canal, 1991) 

All research for GPC show GPC plays a positive role in adverse groups including health young people. GPC has significant effects on paralytic, senile dementia patients and other people with problems of cerebral circulation. (Parnetti L, 2001) GPC is a natural protector of all organs, it is concentrated in the human brain, it can prevent apoplexy, Alzheimer’s disease, schizophrenia, bipolar mental disorder, and cerebellar imbalance led by myelin phospholipids collapse. GPC has hydrophily and lipophilicity, which means it is able to be absorbed into the aqueous phase easily, and then it can enter into blood circulation and arrive all organizations, take part in biochemical process in the human body in various ways. GPC plays a considerable role in human nervous system, reproductive system endocrine system, skeletal muscle, kidney, and liver. (Kidd, 2008)The results show GPC is allowed to repair hormone secreting function of the elder, it makes brain glow again. (Govoni, 1992)

1. GPC is the main resource of choline and acetylcholine in human body

As an important nutriment, choline is a main resource of methyl which adjusts other metabolic processes. However, free choline is unstable in aqueous phase, so its content is low in blood and tissues. As an efficient and convenient resources of human choline metabolism, it plays an important role in human metabolism. The research shows, by oral administration and muscular injection, GPC is able to improve choline content in blood and brain in a certain period. (Govoni, 1992) And it will not have the abuse led by having choline. After having GPC, the choline in mice brain will grow by half. What’s more, all brain areas will be full of GPC after using GPC, especially the GPC content of the pituitary will be higher than other areas. (Lacomba, 1992)

GPC is also the principal transmitter of chemical substance and resource of acetylcholine. (Farooqui, 2000) It has a significant importance in formation, dilatation, update, repair and adjustment of plasticity of brain wave. After taking GPC orally, the GPC content in mice brain improves greatly, particularly the bumps on the hippocampus in brain. (Tayebati, 2011) On the other hand, GPC is also a unique cell protective agent. GPC is able to compose acetylcholine which is essential for cell growth and reproduction. 

2. GPC is able to improve memory of young people

Medicine scopolamine may run out of acetylcholine stored in brain, which may lead to momentary cognitive impairment. Cognitive impairment may exist for several hours. Investigators make volunteers take GPC for 7-10 days(Canal, 1991), the volunteers are injected scopolamine, and they are tested after 6 hours. The results show GPC has great inhibiting effect on amnesia made by scopolamine. It proves GPC has a great positive effect on the improvement of memory. 

3. GPC contributes to resistance to cognitive decline

GPC has a notable effect for resisting vascular dementia. A clinic research of 789 vascular dementia patients shows(Perri, 1991), after taking GPC for three months, the clinical signs of these patients including cognition, emotion, symptom, and fatigue have been effectively improved.

 Alzheimer’s disease is improved evidently by GPC. Parietti(Parietti, 2001) has a test of 6 groups including 565 dements, the clinic result shows GPC is able to advance location ability, language ability, memory and attention. In the meantime, The psychosis assessment of dements are improved 10-26% by GPC.

4. GPC helps to recover brain apoplexy and other brain hurt

GPC has positive effect on recovering from brain apoplexy. The biggest test in record includes 176 hospitals, 2044 patients in Italy.(Barbaga, 1994) In the first phase of GPC muscle injection treatment, the neural functions has recovered 20-30%. In the succedent oral GPC treatment phase, there is 12-15% improvement in psychosis assessment. The research shows GPC helps more than 95% patients at least. Above all, GPC shows no negative effect on human body by blood test and lab assessment. All results show, GPC has significant and particular effects on the treatment and recovering of brain injurers.

5. GPC can promote the release of growth hormone

The supplement of GPC is able to promote the release of hormone in brain, and release of growth hormone by pituitary in particular. As we all known, pituitary controls the production of various hormone in human body, it can release growth hormone and other hormone which is responsible for body maintain and update. When people enter into middle age, the hormone in human body declines, which may leads to negative change for body(Vega, 1993). The intervene of GPC can not only help pituitary produce hormone, but also has no obvious side effect.

Reference:

Barbaga S. G., Barbagallo M., Giordano M.,et al. Alpha-glycerophosphocholine in the Mental Recovery of Cerebral Ischemic Attacks[J]. Annals of the New York Academy of Sciences, 1994,717; 253-269

Canal N, Franceschi M, Alberoni M, et al. Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.[J]. International Journal of Clinical Pharmacology Therapy & Toxicology, 1991, 29(3):103-7.

Ceda G P, Ceresini G, Denti L, et al. alpha-Glycerylphosphorylcholine administration increases the GH responses to GHRH of young and elderly subjects.[J]. Hormone & Metabolic Research, 1992, 24(3):119-21.

Curatolo W, Radhakrishnan R, Gupta C M, et al. Photoactivatable carbene-generating phospholipids: physical properties and use in detection of phase separations in lipid mixtures.[J]. Biochemistry, 1981, 20(5):1374-8.

Farooqui A A, Horrocks L A, Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders[J]. Chemistry & Physics of Lipids, 2000, 106(1):1-29.

Govoni S, Lopez C M, Battaini F, et al. Chronic treatment with an acetylcholine synthesis precursor, alpha-glycerylphosphorylcholine, alters brain parameters linked to cholinergic transmission and passive avoidance behavior[J]. Drug Development Research, 1992, 26(26):439-447.

Kidd P M. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: Current understanding and progress toward integrative prevention[J]. Alternative Medicine Review A Journal of Clinical Therapeutic, 2008, 13(2):85-115.

Kidd P M. GlyceroPhosphoCholine (GPC), Mind-Body Nutrient for Active Living And Healthy Aging[M]. St. George: Total Health Communications Inc., 2007: 1-21

Lacomba C, Cagiano R, Maci O, et al. Effects of L-alpha-glycerylphosphorylcholine on the EEG power spectrum in the rat[J]. Drug Development Research, 1992, 26(1):101–107.

Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data[J]. Mechanisms of Ageing & Development, 2001, 122(16):2041-2055.

Perri D. R.,Coppola G,Ambrosio L. A.,et al. A Multicentre Trial to Evaluate the

Efficacy and Tolerability of Alphaglycerylphosphorylcholine versus Cytosine

Diphosphocholine in Patients with Vascular Dementia[J]. The Journal of International Medical Research, 1991,19(4): 330-341

Tayebati S K, Tomassoni D, Stefano A D, et al. Effect of choline-containing phospholipids on brain cholinergic transporters in the rat.[J]. Journal of the Neurological Sciences, 2011, 302(1-2):49–57.

Vega J A, Cavallotti C, Valle M E D, et al. Nerve growth factor receptor immunoreactivity in the cerebellar cortex of aged rats: effect of choline alfoscerate treatment.[J]. Mechanisms of Ageing & Development, 1993, 69(1-2):119–127.